Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Colloid Interface Sci ; 545: 259-268, 2019 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-30897421

RESUMO

Hepatitis C virus-like particles (VLPs) are being developed as a quadrivalent vaccine candidate, eliciting both humoral and cellular immune responses in animal trials. Biophysical, biomechanical and biochemical properties are important for virus and VLP interactions with host cells and recognition by the immune system. Atomic force microscopy (AFM) is a powerful tool for visualizing surface topographies of cells, bionanoparticles and biomolecules, and for determining biophysical and biomechanical attributes such as size and elasticity. In this work, AFM was used to define morphological and nanomechanical properties of VLPs representing four common genotypes of hepatitis C virus. Significant differences in size of the VLPs were observed, and particles demonstrated a wide range of elasticity. Ordered packing of the core and potentially envelope glycoproteins was observed on the surfaces of the VLPs, but detailed structural characterization was hindered due to intrinsic dynamic fluctuations or AFM probe-induced damage of the VLPs. All VLPs were shown to be glycosylated in a manner similar to native viral particles. Together, the results presented in this study further our understanding of the nanostructure of hepatitis C VLPs, and should influence their uptake as viable vaccine candidates.


Assuntos
Nanopartículas/metabolismo , Vacinas contra Hepatite Viral/metabolismo , Vírion/metabolismo , Transporte Biológico , Proteínas de Transporte/metabolismo , Linhagem Celular , Elasticidade , Genótipo , Hepacivirus/metabolismo , Humanos , Lectinas/química , Lectinas/metabolismo , Microscopia de Força Atômica/métodos , Nanopartículas/química , Tamanho da Partícula , Propriedades de Superfície , Proteínas do Envelope Viral/metabolismo , Vacinas contra Hepatite Viral/química , Vírion/química
2.
PLoS One ; 10(11): e0142349, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26556235

RESUMO

More than 170 million individuals worldwide are infected with hepatitis C virus (HCV), and up to an estimated 30% of chronically infected individuals will go on to develop progressive liver disease. Despite the recent advances in antiviral treatment of HCV infection, it remains a major public health problem. Thus, development of an effective vaccine is urgently required. In this study, we constructed novel adeno-associated virus (AAV) vectors expressing the full-length NS3 or NS3/4 protein of HCV genotype 1b. The expression of the NS3 or NS3/4 protein in HepG2 cells was confirmed by western blotting. C57BL/6 mice were intramuscularly immunised with a single injection of AAV vectors, and the resultant immune response was investigated. The AAV2/rh32.33.NS3/4 vaccine induced stronger humoral and cellular responses than did the AAV2/rh32.33.NS3 vaccine. Our results demonstrate that AAV-based vaccines exhibit considerable potential for the development of an effective anti-HCV vaccine.


Assuntos
Dependovirus/imunologia , Hepatite C/imunologia , Vacinas de DNA/imunologia , Proteínas não Estruturais Virais/imunologia , Animais , Dependovirus/genética , Feminino , Vetores Genéticos , Células Hep G2 , Hepatite C/genética , Humanos , Imunoglobulina G/sangue , Camundongos Endogâmicos C57BL , RNA Mensageiro/metabolismo , Linfócitos T/citologia , Vacinas de DNA/genética , Vacinas de DNA/metabolismo , Vacinas contra Hepatite Viral/genética , Vacinas contra Hepatite Viral/isolamento & purificação , Vacinas contra Hepatite Viral/metabolismo , Proteínas não Estruturais Virais/genética , Proteínas não Estruturais Virais/metabolismo
3.
J Mol Recognit ; 28(8): 492-505, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25727409

RESUMO

Hepatitis C virus (HCV) is considered as a foremost cause affecting numerous human liver-related disorders. An effective immuno-prophylactic measure (like stable vaccine) is still unavailable for HCV. We perform an in silico analysis of nonstructural protein 5B (NS5B) based CD4 and CD8 epitopes that might be implicated in improvement of treatment strategies for efficient vaccine development programs against HCV. Here, we report on effective utilization of knowledge obtained from multiple sequence alignment and phylogenetic analysis for investigation and evaluation of candidate epitopes that have enormous potential to be used in formulating proficient vaccine, embracing multiple strains prevalent among major geographical locations. Mutational variability data discussed herein focus on discriminating the region under active evolutionary pressure from those having lower mutational potential in existing experimentally verified epitopes, thus, providing a concrete framework for designing an effective peptide-based vaccine against HCV. Additionally, we measured entropy distribution in NS5B residues and pinpoint the positions in epitopes that are more susceptible to mutations and, thus, account for virus strategy to evade the host immune system. Findings from this study are expected to add more details on the sequence and structural aspects of NS5B protein, ultimately facilitating our understanding about the pathophysiology of HCV and assisting advance studies on the function of NS5B antigen on the epitope level. We also report on the mutational crosstalk between functionally important coevolving residues, using correlated mutation analysis, and identify networks of coupled mutations that represent pathways of allosteric communication inside and among NS5B thumb, finger, and palm domains.


Assuntos
Biologia Computacional , Mapeamento de Epitopos , Epitopos/metabolismo , Variação Genética , Filogenia , Proteínas não Estruturais Virais/genética , Sequência de Aminoácidos , Análise Mutacional de DNA , Entropia , Hepacivirus/imunologia , Humanos , Vacinas contra Hepatite Viral/química , Vacinas contra Hepatite Viral/metabolismo , Vacinas contra Hepatite Viral/uso terapêutico , Proteínas não Estruturais Virais/química , Proteínas não Estruturais Virais/metabolismo
4.
Vopr Virusol ; 58(2): 21-8, 2013.
Artigo em Russo | MEDLINE | ID: mdl-23785766

RESUMO

A promising approach to construction of antiviral vaccines consists in activation of cellular immunity with the DNA vaccines. The goal of this work was to evaluate the efficacy of genetic immunization of mice with DNA pcNS3-NS5B encoding five hepatitis C virus (HCV) nonstructural proteins: NS3, NS4A, NS4B, NS5A, and NS5B in comparison with plasmids containing genes of same individual nonstructural proteins. The DNA constructions were injected intramuscularly in DBA mice three times. The humoral immune response was assessed with ELISA; cellular immune response--in blast transformation reaction, by quantitation of CD4+ and CD8+ T cell proliferation using flow cytofluorometry, by intracellular synthesis and secretion of IFN-gamma and IL-2 in ELISpot and ELISA. It was found that the functionally active T cell response was achieved to antigens presenting NS3, NS4, NS5A, and NS5B epitopes of different HCV genotypes in response to pcNS3-NS5B plasmid and was stronger than that to plasmids carrying individual genes. A high proliferation rate of CD4+ T cells, secretion of IL-2 and IFN-gamma, induction of anti-NS3 and anti-NS5B IgG2a were demonstrated. These findings indicate that DNA construction pcNS3-NS5B is one of promising candidates for anti-HCV vaccine developing.


Assuntos
Hepacivirus/imunologia , Hepatite C/imunologia , Vacinas de DNA/farmacologia , Vacinas contra Hepatite Viral/farmacologia , Proteínas não Estruturais Virais/imunologia , Animais , Anticorpos Antivirais/sangue , Anticorpos Antivirais/imunologia , Linhagem Celular Tumoral , Hepacivirus/genética , Hepacivirus/metabolismo , Hepatite C/genética , Hepatite C/metabolismo , Hepatite C/prevenção & controle , Humanos , Imunidade Celular/efeitos dos fármacos , Imunidade Celular/genética , Imunidade Humoral/efeitos dos fármacos , Imunidade Humoral/genética , Interferon gama/biossíntese , Interferon gama/imunologia , Interleucina-2/biossíntese , Interleucina-2/imunologia , Camundongos , Linfócitos T/imunologia , Linfócitos T/metabolismo , Vacinas de DNA/genética , Vacinas de DNA/imunologia , Vacinas de DNA/metabolismo , Vacinas contra Hepatite Viral/genética , Vacinas contra Hepatite Viral/imunologia , Vacinas contra Hepatite Viral/metabolismo , Proteínas não Estruturais Virais/biossíntese , Proteínas não Estruturais Virais/genética
5.
J Immunol ; 188(10): 5177-88, 2012 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-22508927

RESUMO

Vaccines designed to prevent or to treat hepatitis C viral infection must achieve maximum cross-reactivity against widely divergent circulating strains. Rational approaches for sequence selection to maximize immunogenicity and minimize genetic distance across circulating strains may enhance vaccine induction of optimal cytotoxic T cell responses. We assessed T cell recognition of potential hepatitis C virus (HCV) vaccine sequences generated using three rational approaches: combining epitopes with predicted tight binding to the MHC, consensus sequence (most common amino acid at each position), and representative ancestral sequence that had been derived using bayesian phylogenetic tools. No correlation was seen between peptide-MHC binding affinity and frequency of recognition, as measured by an IFN-γ T cell response in HLA-matched HCV-infected individuals. Peptides encoding representative, consensus, and natural variant sequences were then tested for the capacity to expand CD8 T cell populations and to elicit cross-reactive CD8 T cell responses. CD8(+) T cells expanded with representative sequence HCV generally more broadly and robustly recognized highly diverse circulating HCV strains than did T cells expanded with either consensus sequence or naturally occurring sequence variants. These data support the use of representative sequence in HCV vaccine design.


Assuntos
Hepacivirus/imunologia , Hepatite C/imunologia , Fragmentos de Peptídeos/imunologia , Fragmentos de Peptídeos/metabolismo , Linhagem Celular , Células Cultivadas , Estudos de Coortes , Sequência Consenso/imunologia , Reações Cruzadas/imunologia , Antígenos HLA/imunologia , Hepatite C/metabolismo , Hepatite C/virologia , Humanos , Fragmentos de Peptídeos/síntese química , Estudos Prospectivos , Vacinas contra Hepatite Viral/síntese química , Vacinas contra Hepatite Viral/imunologia , Vacinas contra Hepatite Viral/metabolismo
6.
Mol Biol (Mosk) ; 44(2): 275-83, 2010.
Artigo em Russo | MEDLINE | ID: mdl-20586188

RESUMO

In spite of extensive research, no effective vaccine against hepatitis C virus (HCV) has been developed so far. DNA immunization is a potent technique of vaccine design strongly promoting the cellular arm of immune response. The genes encoding nonstructural HCV proteins (NS2-NS5B) are promising candidates for vaccine development. NS5A is a protein involved in viral pathogenesis, in the induction of immune response, and probably in viral resistance to interferon treatment. The objective of this study was to construct a DNA vaccine encoding NS5A protein and evaluate its immunogenicity. A plasmid encoding a full-size NS5A protein was produced using the pcDNA3.1 (+) vector for eukaryotic expression system. The expression of the NS5A gene was confirmed by immunoperoxidase staining of the transfected eukaryotic cells with anti-NS5A monoclonal antibodies. Triple immunization of mice with the plasmid vaccine induced a pronounced cellular immune response against abroad spectrum of NSSA epitopes as assessed by T-cell proliferation andsecretion of antiviral cytokines IFN-gamma and IL-2. In in vitro T-cell stimulation experiments, NS5A-derived antigens were modeled by synthetic peptides, recombinant proteins of various genotypes, and phages carrying exposed NS5A peptides. A novel immunomodulator Immunomax showed high adjuvant activity in DNA immunization. The data obtained indicate that the suggested DNA construct has a strong potential in the development of the gene vaccines against hepatitis C.


Assuntos
Hepacivirus/imunologia , Hepatite C/imunologia , Plasmídeos/farmacologia , Linfócitos T/imunologia , Vacinas de DNA/farmacologia , Vacinas contra Hepatite Viral/farmacologia , Proteínas não Estruturais Virais/imunologia , Animais , Linhagem Celular Tumoral , Proliferação de Células , Chlorocebus aethiops , Feminino , Hepacivirus/genética , Hepacivirus/metabolismo , Hepatite C/genética , Hepatite C/metabolismo , Hepatite C/prevenção & controle , Humanos , Imunidade Celular , Interferon gama/biossíntese , Interferon gama/imunologia , Interleucina-2/biossíntese , Interleucina-2/imunologia , Camundongos , Plasmídeos/genética , Plasmídeos/imunologia , Plasmídeos/metabolismo , Linfócitos T/metabolismo , Vacinas de DNA/genética , Vacinas de DNA/imunologia , Vacinas de DNA/metabolismo , Células Vero , Vacinas contra Hepatite Viral/genética , Vacinas contra Hepatite Viral/imunologia , Vacinas contra Hepatite Viral/metabolismo , Proteínas não Estruturais Virais/biossíntese , Proteínas não Estruturais Virais/genética
7.
J Biol Chem ; 283(39): 26340-8, 2008 Sep 26.
Artigo em Inglês | MEDLINE | ID: mdl-18667425

RESUMO

Disulfide bonding contributes to the function and antigenicity of many viral envelope glycoproteins. We assessed here its significance for the hepatitis C virus E2 envelope protein and a counterpart deleted for hypervariable region-1 (HVR1). All 18 cysteine residues of the antigens were involved in disulfides. Chemical reduction of up to half of these disulfides was compatible with anti-E2 monoclonal antibody reaction, CD81 receptor binding, and viral entry, whereas complete reduction abrogated these properties. The addition of 5,5'-dithiobis-2-nitrobenzoic acid had no effect on viral entry. Thus, E2 function is only weakly dependent on its redox status, and cell entry does not require redox catalysts, in contrast to a number of enveloped viruses. Because E2 is a major neutralizing antibody target, we examined the effect of disulfide bonding on E2 antigenicity. We show that reduction of three disulfides, as well as deletion of HVR1, improved antibody binding for half of the patient sera tested, whereas it had no effect on the remainder. Small scale immunization of mice with reduced E2 antigens greatly improved serum reactivity with reduced forms of E2 when compared with immunization using native E2, whereas deletion of HVR1 only marginally affected the ability of the serum to bind the redox intermediates. Immunization with reduced E2 also showed an improved neutralizing antibody response, suggesting that potential epitopes are masked on the disulfide-bonded antigen and that mild reduction may increase the breadth of the antibody response. Although E2 function is surprisingly independent of its redox status, its disulfide bonds mask antigenic domains. E2 redox manipulation may contribute to improved vaccine design.


Assuntos
Anticorpos Antivirais/imunologia , Hepacivirus/imunologia , Antígenos da Hepatite C/imunologia , Proteínas do Envelope Viral/imunologia , Sequência de Aminoácidos , Animais , Anticorpos Antivirais/genética , Anticorpos Antivirais/metabolismo , Formação de Anticorpos/genética , Formação de Anticorpos/imunologia , Antígenos CD/genética , Antígenos CD/imunologia , Antígenos CD/metabolismo , Linhagem Celular , Dissulfetos/química , Dissulfetos/imunologia , Dissulfetos/metabolismo , Ácido Ditionitrobenzoico/química , Hepacivirus/química , Hepacivirus/genética , Hepacivirus/metabolismo , Antígenos da Hepatite C/química , Antígenos da Hepatite C/genética , Antígenos da Hepatite C/metabolismo , Antígenos da Hepatite C/farmacologia , Humanos , Imunização , Camundongos , Camundongos Endogâmicos BALB C , Oxirredução , Estrutura Terciária de Proteína/genética , Deleção de Sequência , Reagentes de Sulfidrila/química , Tetraspanina 28 , Proteínas do Envelope Viral/química , Proteínas do Envelope Viral/genética , Proteínas do Envelope Viral/metabolismo , Proteínas do Envelope Viral/farmacologia , Vacinas contra Hepatite Viral/química , Vacinas contra Hepatite Viral/genética , Vacinas contra Hepatite Viral/imunologia , Vacinas contra Hepatite Viral/metabolismo , Vacinas contra Hepatite Viral/farmacologia , Internalização do Vírus
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA